Galectin Therapeutics (GALT) Price Target Raised by 83.33% to $11.22
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 21 2025
0mins
Source: NASDAQ.COM
Price Target Update: The average one-year price target for Galectin Therapeutics (NasdaqCM:GALT) has been raised to $11.22 per share, reflecting an 83.33% increase from the previous estimate of $6.12, with a potential upside of 156.16% from the last closing price of $4.38.
Fund Sentiment: There are currently 122 funds reporting positions in Galectin Therapeutics, a decrease of 27 funds (18.12%) from the last quarter, while the average portfolio weight dedicated to GALT has increased by 41.86%.
Shareholder Activity: Notable shareholders include Vanguard Total Stock Market Index Fund and Advisor Group Holdings, with varying changes in their shareholdings, including increases in portfolio allocations for some funds.
Market Outlook: The put/call ratio for GALT stands at 0.09, indicating a bullish sentiment among investors, suggesting optimism about the stock's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GALT
Wall Street analysts forecast GALT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.570
Low
11.00
Averages
11.00
High
11.00
Current: 2.570
Low
11.00
Averages
11.00
High
11.00
About GALT
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galectin Therapeutics Q1 Earnings Report Analysis
- Earnings Performance: Galectin Therapeutics reported a Q1 GAAP EPS of -$0.08, missing expectations by $0.02, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Cash Position: As of March 31, 2026, the company had $14.1 million in cash and cash equivalents, along with an additional $10 million available under a line of credit, providing a financial buffer to support operations in the near term.
- Funding Plans: The company believes it has sufficient cash to fund its planned operations and R&D activities through May 2027, reflecting a cautious approach to financial management despite profitability pressures, ensuring continued progress in research.
- Market Reaction Outlook: Although the GAAP EPS showed slight improvement, the overall financial performance may not significantly boost market confidence, potentially leading to stock price volatility, prompting investors to closely monitor subsequent R&D developments and market responses.
See More
Galectin Therapeutics Reports Positive Phase 2b Results for Belapectin in MASH Cirrhosis
- Clinical Trial Results: Galectin Therapeutics published promising results from the Phase 2b NAVIGATE trial for belapectin in treating MASH cirrhosis and portal hypertension in the journal Hepatology, indicating the drug's potential in reducing complications.
- Drug Mechanism: Belapectin is an investigational drug that inhibits galectin-3 to treat fibrosis and inflammation caused by MASH cirrhosis, having received Fast Track designation from the FDA, highlighting its urgent development status.
- Trial Design: The NAVIGATE trial was a global randomized controlled study evaluating belapectin's efficacy in patients without esophageal varices, showing a numerical reduction in varices incidence and improvements in non-invasive fibrosis markers like Liver Stiffness Measure (LSM) and Enhanced Liver Fibrosis (ELF).
- Market Reaction: GALT is currently trading at $2.36, up 12.38%, reflecting positive market sentiment towards the clinical results, which may provide financial support for the company's future development.
See More
Galectin Therapeutics Reports FY EPS Beat Expectations
- Earnings Performance: Galectin Therapeutics reported a FY GAAP EPS of -$0.48, beating expectations by $0.01, indicating some improvement in financial management despite still being in a loss position.
- Cash Flow Status: As of December 31, 2025, the company had $17.7 million in unrestricted cash and cash equivalents, along with an additional $10 million available under a line of credit, providing a financial cushion for future operations.
- Sufficient Funding: The company believes that its current cash flow is adequate to fund planned operations and R&D activities through April 2027, reflecting confidence in its future growth prospects.
- Therapeutic Progress: Galectin Therapeutics is discussing updated results for Belapectin in the treatment of MASH cirrhosis and portal hypertension, indicating ongoing efforts in R&D and potential market opportunities.
See More
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
- Investigation Launched: Pomerantz LLP is investigating Galectin Therapeutics Inc. and its executives for potential securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock volatility.
- FDA Response: On December 19, 2025, Galectin announced that the FDA provided a written response to its meeting request regarding the belapectin development program, indicating alignment on the proposed patient population for a registration trial, but unresolved key aspects of the trial design may delay clinical trial progress.
- Stock Price Drop: Following the FDA news, Galectin's stock price fell by $1.78, or 28.9%, closing at $4.38 per share, reflecting market concerns and diminished confidence in the company's future prospects.
- Legal Matters: Pomerantz LLP, a prominent securities class action law firm, has been advocating for the rights of securities fraud victims for over 85 years; unfavorable investigation outcomes could lead to significant damages against the company, further impacting its financial health.
See More
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
- Securities Fraud Investigation: Pomerantz LLP is investigating Galectin Therapeutics and its executives for potential securities fraud and other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- FDA Meeting Update: On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, indicating alignment on the patient population but leaving key trial design aspects unresolved.
- Stock Price Plunge: Following the FDA news, Galectin's stock price fell by $1.78, or 28.9%, closing at $4.38 per share, reflecting market concerns about the company's future prospects.
- Legal Background: Pomerantz LLP, a prominent securities class action law firm with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, potentially offering legal support to affected investors.
See More
Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial
- Significant Stock Decline: Galectin Therapeutics experienced a stock price drop of $1.78, or 28.9%, closing at $4.38 per share following the FDA's response regarding its belapectin clinical trial, indicating market concerns about the company's future prospects.
- Change in FDA Communication: The FDA's conversion of Galectin's request for an in-person or teleconference meeting into a written response highlights unresolved issues in key trial design aspects, which may impact the progress of its clinical trials and registration applications.
- Follow-Up Meeting Plans: Galectin plans to pursue a follow-up Type C meeting to finalize remaining components of its clinical trial design, and while there is alignment with the FDA on the proposed patient population, unresolved key design issues could delay trial progress.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Galectin and its executives have engaged in securities fraud or other unlawful business practices, potentially exposing investors to further legal risks and financial losses.
See More
Galectin Therapeutics Q1 Earnings Report Analysis
- Earnings Performance: Galectin Therapeutics reported a Q1 GAAP EPS of -$0.08, missing expectations by $0.02, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Cash Position: As of March 31, 2026, the company had $14.1 million in cash and cash equivalents, along with an additional $10 million available under a line of credit, providing a financial buffer to support operations in the near term.
- Funding Plans: The company believes it has sufficient cash to fund its planned operations and R&D activities through May 2027, reflecting a cautious approach to financial management despite profitability pressures, ensuring continued progress in research.
- Market Reaction Outlook: Although the GAAP EPS showed slight improvement, the overall financial performance may not significantly boost market confidence, potentially leading to stock price volatility, prompting investors to closely monitor subsequent R&D developments and market responses.
See More
Galectin Therapeutics Reports Positive Phase 2b Results for Belapectin in MASH Cirrhosis
- Clinical Trial Results: Galectin Therapeutics published promising results from the Phase 2b NAVIGATE trial for belapectin in treating MASH cirrhosis and portal hypertension in the journal Hepatology, indicating the drug's potential in reducing complications.
- Drug Mechanism: Belapectin is an investigational drug that inhibits galectin-3 to treat fibrosis and inflammation caused by MASH cirrhosis, having received Fast Track designation from the FDA, highlighting its urgent development status.
- Trial Design: The NAVIGATE trial was a global randomized controlled study evaluating belapectin's efficacy in patients without esophageal varices, showing a numerical reduction in varices incidence and improvements in non-invasive fibrosis markers like Liver Stiffness Measure (LSM) and Enhanced Liver Fibrosis (ELF).
- Market Reaction: GALT is currently trading at $2.36, up 12.38%, reflecting positive market sentiment towards the clinical results, which may provide financial support for the company's future development.
See More
Galectin Therapeutics Reports FY EPS Beat Expectations
- Earnings Performance: Galectin Therapeutics reported a FY GAAP EPS of -$0.48, beating expectations by $0.01, indicating some improvement in financial management despite still being in a loss position.
- Cash Flow Status: As of December 31, 2025, the company had $17.7 million in unrestricted cash and cash equivalents, along with an additional $10 million available under a line of credit, providing a financial cushion for future operations.
- Sufficient Funding: The company believes that its current cash flow is adequate to fund planned operations and R&D activities through April 2027, reflecting confidence in its future growth prospects.
- Therapeutic Progress: Galectin Therapeutics is discussing updated results for Belapectin in the treatment of MASH cirrhosis and portal hypertension, indicating ongoing efforts in R&D and potential market opportunities.
See More
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
- Investigation Launched: Pomerantz LLP is investigating Galectin Therapeutics Inc. and its executives for potential securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock volatility.
- FDA Response: On December 19, 2025, Galectin announced that the FDA provided a written response to its meeting request regarding the belapectin development program, indicating alignment on the proposed patient population for a registration trial, but unresolved key aspects of the trial design may delay clinical trial progress.
- Stock Price Drop: Following the FDA news, Galectin's stock price fell by $1.78, or 28.9%, closing at $4.38 per share, reflecting market concerns and diminished confidence in the company's future prospects.
- Legal Matters: Pomerantz LLP, a prominent securities class action law firm, has been advocating for the rights of securities fraud victims for over 85 years; unfavorable investigation outcomes could lead to significant damages against the company, further impacting its financial health.
See More
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
- Securities Fraud Investigation: Pomerantz LLP is investigating Galectin Therapeutics and its executives for potential securities fraud and other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- FDA Meeting Update: On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, indicating alignment on the patient population but leaving key trial design aspects unresolved.
- Stock Price Plunge: Following the FDA news, Galectin's stock price fell by $1.78, or 28.9%, closing at $4.38 per share, reflecting market concerns about the company's future prospects.
- Legal Background: Pomerantz LLP, a prominent securities class action law firm with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, potentially offering legal support to affected investors.
See More
Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial
- Significant Stock Decline: Galectin Therapeutics experienced a stock price drop of $1.78, or 28.9%, closing at $4.38 per share following the FDA's response regarding its belapectin clinical trial, indicating market concerns about the company's future prospects.
- Change in FDA Communication: The FDA's conversion of Galectin's request for an in-person or teleconference meeting into a written response highlights unresolved issues in key trial design aspects, which may impact the progress of its clinical trials and registration applications.
- Follow-Up Meeting Plans: Galectin plans to pursue a follow-up Type C meeting to finalize remaining components of its clinical trial design, and while there is alignment with the FDA on the proposed patient population, unresolved key design issues could delay trial progress.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Galectin and its executives have engaged in securities fraud or other unlawful business practices, potentially exposing investors to further legal risks and financial losses.
See More
